UCB Invests $5 Billion in Georgia Biologics Manufacturing Hub
Event summary
- UCB is building a 460,000 sq ft biologics manufacturing facility in Gwinnett County, Georgia, representing a $5 billion economic impact.
- The facility is expected to create approximately 330 permanent jobs and over 1,000 construction jobs.
- The new campus will serve as a hub for UCB's U.S. Manufacturing Operations and strengthen its global biologics manufacturing network.
- UCB has achieved 16 FDA approvals/expansions since 2021, with 9 in the last three years.
- UCB’s U.S. workforce has grown 73% since 2017, with a 121% increase in R&D roles.
The big picture
UCB’s investment signals a strategic shift towards localized biologics production, driven by a desire to enhance supply chain resilience and reduce reliance on overseas manufacturing. This move aligns with broader trends of reshoring and nearshoring in the pharmaceutical industry, particularly in response to recent geopolitical instability and pandemic-related supply chain disruptions. The facility’s focus on digital technologies underscores a broader industry effort to improve manufacturing efficiency and agility.
What we're watching
- Execution Risk
- The success of the facility hinges on UCB’s ability to integrate advanced technologies like AI and robotics, which could face implementation challenges and delays.
- Regulatory Headwinds
- Increased scrutiny of biopharmaceutical manufacturing processes and potential changes in FDA regulations could impact the facility's operational timeline and compliance costs.
- Talent Acquisition
- Securing and retaining a skilled workforce in advanced manufacturing and biologics production will be critical, potentially leading to wage pressures and competition for talent in the Atlanta area.
Related topics